pain
Conditions
Interventions
1:5 ml normal saline is given to the patients intravenously at 30 minutes before surgery and at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively
2:40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 ho
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. All patients give written informed consent; 2. American Society of Anesthesiologists (ASA) physical status of I or II; 3. 20 years to 55 years; 4. Weight 50~70 kg, BMI 19~24; 5. Duration of operation time in the range of 2-4 hours; 6. A normal leukocytes level before the operation; 7. No alcohol or smoking abuse; 8. Without major trauma, history of psychiatric disease and history of chronic pain; 9. Patients agreement with the trial and having ability to complete the requirements of this study; 10. Patients receiving intravenous patient controlled analgesia (PCA).
Exclusion criteria
Exclusion criteria: 1. Allergy or contraindication to selective COX-2 inhibitors; 2. Received NSAIDs treatments before the operation; 3. Used enzyme inhibitor (such as Ketoconazole, Fluconazole, Itraconazole), enzyme inducer (such as Rifampicin, Phenytoin sodium, Carbamazepine, Dexamethasone), anticoagulant (such as Warfarin, Aspirin) and other drugs which increase the drug toxicity (such as Erythromycin, Clarithromycin, Cyclosporin Ciclosporin, ACE inhibitor or Diuretics, Lithium) from the first 3 days before the operation to postoperative observation period; 4. Blood transfusion, hemodilution measures in the operation; 5. Infection of the incision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relevance between individual differences in COX-2 expression and postoperative pain;The expression of inflammatory mediators and its individual differences; | — |
Secondary
| Measure | Time frame |
|---|---|
| The VAS at rest and PCA sufentanyl consumption is assessed at all corresponding time points;The effects of COX-2 inhibitor on the expression of COX-2 in PMNL and macrophages;The expression of COX-2 in PMNL and macrophages and their individual differences; | — |
Countries
China
Contacts
Public ContactXianwei Zhang
Outcome results
None listed